JHOP Articles

HOPA Abstracts

Biodistribution and Shedding Analysis Following RP1 Oncolytic Immunotherapy Dosing in Patients From the IGNYTE Clinical Trial: Implications for Oncology Pharmacists

Abstract #CR02

Christina Davis, PharmD, BCOP; Praveen K. Bommareddy, PhD, BPharm, MS; Alina Monteagudo, PhD; Mohammed M. Milhem, MD; Joseph J. Sacco, MD; Tawnya Lynn Bowles, MD, et al.

HOPA Abstracts

Characterizing Second-Line and Beyond Treatments for Primary Central Nervous System Lymphomas

Abstract #CR03

Erin K. Yeung, PharmD, BCPS, BCOP; Brian Primeaux, PharmD, BCOP; Chelsea Luo, PharmD, BCOP; Caitlin Linger, PharmD, BCOP; Sheree Chen, PharmD, BCOP; Bryan Do, PharmD, BCOP

HOPA Abstracts

Coordinating Better Outcomes in Multiple Myeloma: An Educational Initiative to Elevate Pharmacist Leadership in Novel Antibodies and CAR-T Therapy

Abstract #CR04

Jeffrey Murray, PharmD, PVI; Carmine DeLuca; Michael Beyer, PVI; Zahra Mahmoudjafari, PharmD; R. Donald Harvey, PharmD

HOPA Abstracts

Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence

Abstract #CR05

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Alicia K. Morgans, MD; Neal D. Shore, MD; Nasreen Khan, PhD; Niculae Constantinovici, MD; Javeed Khan, MSc, et al.

HOPA Abstracts

Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen-Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study

Abstract #CR06

HOPA Abstracts

Evaluating Patient Hesitancy in Receiving a Second Dose of Evusheld (Tixagevimab and Cilgavimab) for COVID-19 Prevention After a Food and Drug Administration Dosing Recommendation Update

Abstract #CR07

HOPA Abstracts

First-Line Nivolumab + Ipilimumab + Chemotherapy Versus Chemotherapy Alone in Metastatic Non–Small Cell Lung Cancer: CheckMate 9LA 4-Year Clinical Update

Abstract #CR08

HOPA Abstracts

Impact of Frailty on Outcomes After CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Abstract #CR09